Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice.


Journal

Seminars in liver disease
ISSN: 1098-8971
Titre abrégé: Semin Liver Dis
Pays: United States
ID NLM: 8110297

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 3 5 2019
medline: 30 4 2020
entrez: 4 5 2019
Statut: ppublish

Résumé

Drug-induced liver injury (DILI) is the leading cause of acute liver failure (ALF) in developed countries. The extremely variable phenotype of DILI, both in presentation and in severity, is one of the distinctive characteristics of the disease and one of the major challenges that hepatologists face when assessing hepatotoxicity cases. A new Hy's law that more accurately predicts the risk of ALF related to DILI has been proposed and validated. Other prognostic scoring algorithms for the early identification of DILI patients who may go on to develop ALF have been developed as it is of most clinical relevance to stratify patients for closer monitoring. Recent data indicate that acute DILI often presents a more prolonged resolution or evolves into chronicity at a higher frequency than other forms of acute liver injury. Risk factors for chronicity, specific phenotypes, and histological features are discussed in this study. Biomarkers to predict DILI outcome are in need.

Identifiants

pubmed: 31049898
doi: 10.1055/s-0039-1685519
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

381-394

Informations de copyright

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Déclaration de conflit d'intérêts

None.

Auteurs

Fernando Bessone (F)

Hospital Provincial del Centenario, University of Rosario School of Medicine, Rosario, Argentina.

Mercedes Robles-Diaz (M)

Unidad de Gestión Clínica de Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Universidad de Málaga, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Nelia Hernandez (N)

Facultad de Medicina, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay.

Inmaculada Medina-Caliz (I)

Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Universidad de Málaga, Hospital Universitario Virgen de la Victoria, Málaga, Spain.

M Isabel Lucena (MI)

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Universidad de Málaga, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
Unidad Investigación Clínica y Ensayos Clínicos (UICEC)-IBIMA, Plataforma Spanish Clinical Research Network (SCReN), Málaga, Spain.

Raul J Andrade (RJ)

Unidad de Gestión Clínica de Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Universidad de Málaga, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH